191 related articles for article (PubMed ID: 8611058)
21. Naltrexone for the treatment of alcoholism: a meta-analysis of randomized controlled trials.
Srisurapanont M; Jarusuraisin N
Int J Neuropsychopharmacol; 2005 Jun; 8(2):267-80. PubMed ID: 15850502
[TBL] [Abstract][Full Text] [Related]
22. A randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of concurrent alcohol use disorder and pathological gambling.
Toneatto T; Brands B; Selby P
Am J Addict; 2009; 18(3):219-25. PubMed ID: 19340640
[TBL] [Abstract][Full Text] [Related]
23. Naltrexone in the treatment of alcoholism: predicting response to naltrexone.
Volpicelli JR; Clay KL; Watson NT; O'Brien CP
J Clin Psychiatry; 1995; 56 Suppl 7():39-44. PubMed ID: 7673104
[TBL] [Abstract][Full Text] [Related]
24. Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis.
O'Malley SS; Krishnan-Sarin S; Farren C; Sinha R; Kreek MJ
Psychopharmacology (Berl); 2002 Feb; 160(1):19-29. PubMed ID: 11862370
[TBL] [Abstract][Full Text] [Related]
25. A 6-month controlled naltrexone study: combined effect with cognitive behavioral therapy in outpatient treatment of alcohol dependence.
Balldin J; Berglund M; Borg S; Månsson M; Bendtsen P; Franck J; Gustafsson L; Halldin J; Nilsson LH; Stolt G; Willander A
Alcohol Clin Exp Res; 2003 Jul; 27(7):1142-9. PubMed ID: 12878920
[TBL] [Abstract][Full Text] [Related]
26. Alcohol dependence: after the withdrawal phase. Long-term abstinence: better health and psychosocial status. Psychosocial support for a chronic disorder. Some drugs are useful adjuncts to medical support.
Prescrire Int; 2009 Oct; 18(103):222-3. PubMed ID: 19882797
[No Abstract] [Full Text] [Related]
27. Naltrexone (50 mg) plus psychotherapy in alcohol-dependent patients: a meta-analysis of randomized controlled trials.
Jarosz J; Miernik K; Wąchal M; Walczak J; Krumpl G
Am J Drug Alcohol Abuse; 2013 May; 39(3):144-60. PubMed ID: 23721530
[TBL] [Abstract][Full Text] [Related]
28. Urge-specific and lifestyle coping strategies of alcoholics: relationships of specific strategies to treatment outcome.
Dolan SL; Rohsenow DJ; Martin RA; Monti PM
Drug Alcohol Depend; 2013 Feb; 128(1-2):8-14. PubMed ID: 22898437
[TBL] [Abstract][Full Text] [Related]
29. Social network moderators of naltrexone and behavioral treatment effects on heavy drinking in the COMBINE study.
Worley MJ; Witkiewitz K; Brown SA; Kivlahan DR; Longabaugh R
Alcohol Clin Exp Res; 2015 Jan; 39(1):93-100. PubMed ID: 25623409
[TBL] [Abstract][Full Text] [Related]
30. Naltrexone vs Placebo for the Treatment of Alcohol Dependence: A Randomized Clinical Trial.
Oslin DW; Leong SH; Lynch KG; Berrettini W; O'Brien CP; Gordon AJ; Rukstalis M
JAMA Psychiatry; 2015 May; 72(5):430-7. PubMed ID: 25760804
[TBL] [Abstract][Full Text] [Related]
31. A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse.
Chick J; Anton R; Checinski K; Croop R; Drummond DC; Farmer R; Labriola D; Marshall J; Moncrieff J; Morgan MY; Peters T; Ritson B
Alcohol Alcohol; 2000; 35(6):587-93. PubMed ID: 11093966
[TBL] [Abstract][Full Text] [Related]
32. Outcome predictors for problem drinkers treated with combined cognitive behavioral therapy and naltrexone.
Vuoristo-Myllys S; Lipsanen J; Lahti J; Kalska H; Alho H
Am J Drug Alcohol Abuse; 2014 Mar; 40(2):103-10. PubMed ID: 24456403
[TBL] [Abstract][Full Text] [Related]
33. Naltrexone's effects on reactivity to alcohol cues among alcoholic men.
Rohsenow DJ; Monti PM; Hutchison KE; Swift RM; Colby SM; Kaplan GB
J Abnorm Psychol; 2000 Nov; 109(4):738-42. PubMed ID: 11195999
[TBL] [Abstract][Full Text] [Related]
34. [Pharmacological features of naltrexone and its use in the treatment of alcohol dependence].
Bieńkowski P
Psychiatr Pol; 2013; 47(1):117-26. PubMed ID: 23888749
[TBL] [Abstract][Full Text] [Related]
35. Reduction of alcohol drinking in young adults by naltrexone: a double-blind, placebo-controlled, randomized clinical trial of efficacy and safety.
O'Malley SS; Corbin WR; Leeman RF; DeMartini KS; Fucito LM; Ikomi J; Romano DM; Wu R; Toll BA; Sher KJ; Gueorguieva R; Kranzler HR
J Clin Psychiatry; 2015 Feb; 76(2):e207-13. PubMed ID: 25742208
[TBL] [Abstract][Full Text] [Related]
36. Medical management of alcohol dependence: clinical use and limitations of naltrexone treatment.
Volpicelli JR; Volpicelli LA; O'Brien CP
Alcohol Alcohol; 1995 Nov; 30(6):789-98. PubMed ID: 8679021
[TBL] [Abstract][Full Text] [Related]
37. Placebo-controlled trial of fluoxetine as an adjunct to relapse prevention in alcoholics.
Kranzler HR; Burleson JA; Korner P; Del Boca FK; Bohn MJ; Brown J; Liebowitz N
Am J Psychiatry; 1995 Mar; 152(3):391-7. PubMed ID: 7864265
[TBL] [Abstract][Full Text] [Related]
38. Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized double-blind placebo-controlled multicenter study.
Karhuvaara S; Simojoki K; Virta A; Rosberg M; Löyttyniemi E; Nurminen T; Kallio A; Mäkelä R
Alcohol Clin Exp Res; 2007 Jul; 31(7):1179-87. PubMed ID: 17451401
[TBL] [Abstract][Full Text] [Related]
39. A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol dependence in Taiwan.
Huang MC; Chen CH; Yu JM; Chen CC
Addict Biol; 2005 Sep; 10(3):289-92. PubMed ID: 16109592
[TBL] [Abstract][Full Text] [Related]
40. Predictors of compliance with naltrexone among alcoholics.
Rohsenow DJ; Colby SM; Monti PM; Swift RM; Martin RA; Mueller TI; Gordon A; Eaton CA
Alcohol Clin Exp Res; 2000 Oct; 24(10):1542-9. PubMed ID: 11045863
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
